Subhash Thuluva

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri et al. · EBioMedicine · 2022 · 73 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +9

A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM ₁₉₇ conjugate typhoid vaccine (TyphiBEV ^TM ) in healthy infants, children, and adults in comparison with a licensed comparator

Subhash Thuluva, Vikram Paradkar, Ramesh V. Matur et al. · Human Vaccines & Immunotherapeutics · 2022 · 33 citations · Full text

Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Vaccine · 2022 · 33 citations

Vaccinology, Vaccine Safety, Vaccination +10

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Human Vaccines & Immunotherapeutics · 2023 · 31 citations · Full text

Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies

Subhash Thuluva, Vikram Paradkar, Kishore Turaga et al. · 2022 · 10 citations · Full text